The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma

被引：0
|
作者：
Rachna T Shroff
Mark Yarchoan
Ashley O'Connor
Denise Gallagher
Marianna L Zahurak
Gary Rosner
Chimela Ohaji
Susan Sartorius-Mergenthaler
Vivek Subbiah
Ralph Zinner
Nilofer S Azad
机构：
[1] The University of Texas MD Anderson Cancer Center,
[2] Gastrointestinal Oncology,undefined
[3] Sidney Kimmel Comprehensive Cancer Center,undefined
[4] Johns Hopkins University,undefined
来源：
British Journal of Cancer | 2017年 / 116卷
关键词：
cholangiocarcinoma; trametinib; MEK; pazopanib; VEGF; RAS; angiogenesis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1402 / 1407
页数：5
相关论文
共 50 条
  • [1] The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
    Shroff, Rachna T.
    Yarchoan, Mark
    O'Connor, Ashley
    Gallagher, Denise
    Zahurak, Marianna L.
    Rosner, Gary
    Ohaji, Chimela
    Sartorius-Mergenthaler, Susan
    Subbiah, Vivek
    Zinner, Ralph
    Azad, Nilofer S.
    BRITISH JOURNAL OF CANCER, 2017, 116 (11) : 1402 - 1407
  • [2] Cediranib: a VEGF receptor tyrosine kinase inhibitor
    Sahade, Marina
    Caparelli, Fernanda
    Hoff, Paulo M.
    FUTURE ONCOLOGY, 2012, 8 (07) : 775 - 781
  • [3] Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors
    Langenberg, M. H. G.
    Witteveen, P. O.
    Roodhart, J.
    Lolkema, M. P.
    Verheul, H. M. W.
    Mergui-Roelvink, M.
    Brendel, E.
    Kratzschmar, J.
    Loembe, B.
    Nol-Boekel, A.
    Christensen, O.
    Schellens, J. H. M.
    Voest, E. E.
    ANNALS OF ONCOLOGY, 2011, 22 (11) : 2508 - 2515
  • [4] The MEK inhibitor trametinib for the treatment of advanced melanoma
    Johnson, Douglas B.
    Hames, Megan L.
    Sosman, Jeffrey A.
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (12): : 1341 - 1349
  • [5] Pazopanib: An Oral Multitargeted Tyrosine Kinase Inhibitor for Use in Renal Cell Carcinoma
    LaPlant, Kourtney D.
    Louzon, Paige D.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (06) : 1054 - 1060
  • [6] Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors
    Tolcher, Anthony W.
    Kurzrock, Razelle
    Valero, Vincente
    Gonzalez, Rene
    Heist, Rebecca S.
    Tan, Antoinette R.
    Means-Powell, Julie
    Werner, Theresa L.
    Becerra, Carlos
    Wang, Chenxi
    Leonowens, Cathrine
    Kalyana-Sundaram, Shanker
    Kleha, Joseph F.
    Gauvin, Jennifer
    D'Amelio, Anthony M.
    Ellis, Catherine
    Ibrahim, Nageatte
    Yan, Li
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (04) : 673 - 683
  • [7] Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats
    Yafai, Yousef
    Yang, Xiu Mei
    Niemeyer, Marc
    Nishiwaki, Akiko
    Lange, Johannes
    Wiedemann, Peter
    King, Andrew G.
    Yasukawa, Tsutomu
    Eichler, Wolfram
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2011, 666 (1-3) : 12 - 18
  • [8] A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours
    Infante, Jeffrey R.
    Papadopoulos, Kyriakos P.
    Bendell, Johanna C.
    Patnaik, Amita
    Burris, Howard A., III
    Rasco, Drew
    Jones, Suzanne F.
    Smith, Lon
    Cox, Donna S.
    Durante, Michael
    Bellew, Kevin M.
    Park, Joohyun
    Le, Ngocdiep T.
    Tolcher, Anthony W.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (09) : 2077 - 2085
  • [9] The Combination of Trametinib, a MEK Inhibitor, and Temsirolimus, an mTOR Inhibitor, Radiosensitizes Lung Cancer Cells
    Kim, Seo Yun
    Jeong, Eun-Hui
    Lee, Tae-Gul
    Kim, Hye-Ryoun
    Kim, Cheol Hyeon
    ANTICANCER RESEARCH, 2021, 41 (06) : 2885 - 2894
  • [10] Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies
    Joleen M. Hubbard
    Jun Yin
    Erin L. Schenk
    Rui Qin
    Joel M. Reid
    Carrie Strand
    Jack Fiskum
    Michael Menefee
    Grace Lin
    L. Austin Doyle
    Percy Ivy
    Charles Erlichman
    Alex Adjei
    Paul Haluska
    Brian A. Costello
    Investigational New Drugs, 2022, 40 : 115 - 123
12345